← FDA DRUG APPROVALS

FDA ANDA · ANDA203562

POTASSIUM CHLORIDE

Sponsor: GLENMARK PHARMS LTD

APPLICATION
ANDA203562
TYPE
ANDA
ORIGINAL APPROVAL
2016-07-26
LATEST ACTION
2021-02-26
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

POTASSIUM CHLORIDEPrescription
POTASSIUM CHLORIDE 10MEQ · TABLET, EXTENDED RELEASE · ORAL
POTASSIUM CHLORIDEPrescription
POTASSIUM CHLORIDE 20MEQ · TABLET, EXTENDED RELEASE · ORAL

Approval history

2021-02-26Manufacturing (CMC) · Supplement 3AP
2021-02-26Labeling · Supplement 2 · standardAP
2016-07-26UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →